In the past week, HURA stock has gone up by 1.50%, with a monthly decline of -28.38% and a quarterly plunge of -29.87%. The volatility ratio for the week is 7.61%, and the volatility levels for the last 30 days are 5.69% for TuHURA Biosciences Inc The simple moving average for the last 20 days is -5.54% for HURA stock, with a simple moving average of -38.97% for the last 200 days.
Is It Worth Investing in TuHURA Biosciences Inc (NASDAQ: HURA) Right Now?
The stock has a 36-month beta value of 0.24. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HURA is 24.68M, and at present, short sellers hold a 8.20% of that float. On June 20, 2025, the average trading volume of HURA was 188.70K shares.
HURA) stock’s latest price update
TuHURA Biosciences Inc (NASDAQ: HURA)’s stock price has plunge by 10.20relation to previous closing price of 2.45. Nevertheless, the company has seen a 1.50% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-09 that NEW YORK, June 9, 2025 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)’s merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal rights and options. Vigil Neuroscience, Inc. (NASDAQ: VIGL)’s sale to Sanofi.
Analysts’ Opinion of HURA
Many brokerage firms have already submitted their reports for HURA stocks, with H.C. Wainwright repeating the rating for HURA by listing it as a “Buy.” The predicted price for HURA in the upcoming period, according to H.C. Wainwright is $13 based on the research report published on March 03, 2025 of the current year 2025.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see HURA reach a price target of $11. The rating they have provided for HURA stocks is “Buy” according to the report published on December 19th, 2024.
Maxim Group gave a rating of “Buy” to HURA, setting the target price at $15 in the report published on November 05th of the previous year.
HURA Trading at -23.41% from the 50-Day Moving Average
After a stumble in the market that brought HURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.43% of loss for the given period.
Stock Fundamentals for HURA
The total capital return value is set at -0.85. Equity return is now at value -244.16, with -174.44 for asset returns.
Based on TuHURA Biosciences Inc (HURA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -51.54. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -16.08.
Currently, EBITDA for the company is -17.43 million with net debt to EBITDA at 1.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
To sum up, TuHURA Biosciences Inc (HURA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
